中新集團(601512.SH):擬參投元生創投四期人民幣基金
格隆匯1月17日丨中新集團(601512.SH)公佈,公司擬作為有限合夥人參與投資由蘇州元生私募基金管理合夥企業(有限合夥)發起設立的蘇州工業園區新建元四期股權投資合夥企業(有限合夥)(簡稱“元生創投四期人民幣基金”、“標的基金”),並以現金貨幣方式向標的基金出資不超過1.5億元,且佔比不超過最終基金認繳總額的11%,資金來源為公司自有資金。標的基金採用有限合夥形式設立,規模不低於人民幣15億元且不超過人民幣30億元。
該基金主要對在中國大陸地區設立或運營或與中國大陸地區有其他重大關聯性的醫療健康領域(包括但不限於生物醫藥企業、藥物研發/生產企業、診斷技術/醫療器械企業、醫療服務企業、其他與醫療健康領域相關企業等)的非上市企業(包括在取得顧問委員會同意的前提下參與上市公司非公開發行股票)進行直接或間接的股權或準股權投資或從事與投資相關的活動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.